NYSEAMERICAN:BTX - BioTime Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.27 +0.10 (+8.55 %) (As of 02/19/2019 04:00 PM ET)Previous Close$1.17Today's Range$1.16 - $1.3052-Week Range$0.66 - $2.90Volume1.47 million shsAverage Volume1.03 million shsMarket Capitalization$161.24 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. The company has collaboration with Orbit Biomedical, Ltd. BioTime, Inc. was founded in 1990 and is based in Alameda, California. Receive BTX News and Ratings via Email Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryBiotechnology SectorMedical Current SymbolNYSEAMERICAN:BTX Previous SymbolNYSEMKT:BTX CUSIP09066L10 Webwww.biotimeinc.com Phone+1-510-5213390Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees92 Outstanding Shares126,964,000Market Cap$161.24 million OptionableOptionable BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions What is BioTime's stock symbol? BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX." How were BioTime's earnings last quarter? BioTime, Inc. (NYSEAMERICAN:BTX) announced its earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.11) EPS for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.06. The biotechnology company earned $1.27 million during the quarter, compared to the consensus estimate of $1.75 million. View BioTime's Earnings History. When is BioTime's next earnings date? BioTime is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for BioTime. What price target have analysts set for BTX? 4 analysts have issued 12 month price targets for BioTime's stock. Their forecasts range from $3.00 to $3.50. On average, they anticipate BioTime's share price to reach $3.3333 in the next year. This suggests a possible upside of 162.5% from the stock's current price. View Analyst Price Targets for BioTime. What is the consensus analysts' recommendation for BioTime? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioTime in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioTime. What are Wall Street analysts saying about BioTime stock? Here are some recent quotes from research analysts about BioTime stock: 1. Maxim Group analysts commented, "BioTime announced that its affiliate, OncoCyte (OCX – NR, BTX has 36% stake), reported positive results from an R&D validation study of DetermaVu, a non- invasive, liquid biopsy test for the early diagnosis of lung cancer. On this news, BioTime shares on 1/29 were up ~50%, OncoCyte shares were up over 200%, and even Asterias (AST – NR) shares, a cell therapy company soon to be fully acquired by BioTime, were up ~45%." (1/30/2019) 2. According to Zacks Investment Research, "BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime's research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications. " (1/8/2019) Has BioTime been receiving favorable news coverage? Headlines about BTX stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioTime earned a news impact score of 0.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the next several days. Are investors shorting BioTime? BioTime saw a decline in short interest in January. As of January 31st, there was short interest totalling 9,909,836 shares, a decline of 11.3% from the January 15th total of 11,173,119 shares. Based on an average daily trading volume, of 1,959,934 shares, the days-to-cover ratio is presently 5.1 days. Approximately 8.2% of the company's shares are short sold. View BioTime's Current Options Chain. Who are some of BioTime's key competitors? Some companies that are related to BioTime include Mesoblast (MSB), Emerald Health Therapeutics (EMH), Unity Biotechnology (UBX), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), 22nd Century Group (XXII), IMV (IMV), Enochian Biosciences (ENOB), Kodiak Sciences (KOD), ProMetic Life Sciences (PLI), Monash IVF Group (MVF), IMV (IMV), OncoCyte (OCX) and Emblem (EMC). Who are BioTime's key executives? BioTime's management team includes the folowing people: Dr. Stephana E. Patton, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 48)Mr. Russell L. Skibsted, Chief Financial Officer (Age 60)Mr. William Annett, Pres & CEO of OncoCyte Corp. (Age 65)Mr. Brian M. Culley, CEO , Pres & Director (Age 48)Ms. Brandi L. Roberts, CFO & Sr. VP of Fin. (Age 45) Who are BioTime's major shareholders? BioTime's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.87%), Defender Capital LLC. (3.14%), Geode Capital Management LLC (0.97%), IndexIQ Advisors LLC (0.62%), Two Sigma Investments LP (0.42%) and Bank of New York Mellon Corp (0.32%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime. Which major investors are selling BioTime stock? BTX stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, IndexIQ Advisors LLC and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for BioTime. Which major investors are buying BioTime stock? BTX stock was bought by a variety of institutional investors in the last quarter, including Defender Capital LLC., Two Sigma Investments LP, BlackRock Inc., Two Sigma Advisers LP, Jane Street Group LLC, LPL Financial LLC, Rhumbline Advisers and Geode Capital Management LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime. How do I buy shares of BioTime? Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BioTime's stock price today? One share of BTX stock can currently be purchased for approximately $1.27. How big of a company is BioTime? BioTime has a market capitalization of $161.24 million. BioTime employs 92 workers across the globe. What is BioTime's official website? The official website for BioTime is http://www.biotimeinc.com/. How can I contact BioTime? BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390. MarketBeat Community Rating for BioTime (NYSEAMERICAN BTX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 170 (Vote Outperform)Underperform Votes: 167 (Vote Underperform)Total Votes: 337MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: Why do earnings reports matter?